Stockscreener 앱 받기
24.74
4.69%
1.1185
전일 마감가:
$23.62
열려 있는:
$23.485
하루 거래량:
2.86M
Relative Volume:
1.11
시가총액:
$2.51B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-13.67
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
+12.81%
1개월 성능:
-11.56%
6개월 성능:
+46.93%
1년 성능:
-7.21%
1일 변동 폭
$23.33
$25.25
1주일 범위
$20.23
$25.25
52주 변동 폭
$13.53
$35.25
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
24.76 | 2.40B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.99 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
786.60 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.98 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.97 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
208.73 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Evercore ISI Group Initiates Coverage of Beam Therapeutics (BEAM) with Outperform Recommendation - Nasdaq
Beam Therapeutics (BEAM) Receives New 'Outperform' Rating from E - GuruFocus
How Beam Therapeutics Inc. stock valuations compare to rivals - newser.com
Analyzing drawdowns of Beam Therapeutics Inc. with statistical toolsAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com
Is Beam Therapeutics Inc. stock supported by innovation pipeline2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
How Beam Therapeutics Inc. stock compares to market leaders2025 Biggest Moves & AI Powered Buy/Sell Recommendations - newser.com
Beam Therapeutics (BEAM) Strengthens Cash Position as Key Trials Move Forward - MSN
Historical volatility pattern of Beam Therapeutics Inc. visualized2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
Why retail investors favor Beam Therapeutics Inc. stockJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - newser.com
Real time social sentiment graph for Beam Therapeutics Inc.Market Risk Report & Low Volatility Stock Recommendations - newser.com
9 Best Gene-Editing Stocks to Buy According to Hedge Funds - Insider Monkey
BEAM Therapeutics’ SWOT analysis: genetic medicine stock faces pivotal year ahead - Investing.com Canada
Visualizing Beam Therapeutics Inc. stock with heatmapsOil Prices & Precise Buy Zone Identification - newser.com
Published on: 2025-11-16 06:02:52 - newser.com
(BEAM) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
What hedge fund activity signals for Beam Therapeutics Inc. stockJuly 2025 Snapshot & Reliable Intraday Trade Alerts - newser.com
How buybacks impact Beam Therapeutics Inc. stock value2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
Why Beam Therapeutics Inc. stock is favored by pension fundsPortfolio Value Summary & High Conviction Investment Ideas - newser.com
Beam Therapeutics (BEAM): Exploring Valuation as Clinical Milestones Revitalize Investor Interest - Yahoo Finance
Will Beam Therapeutics Inc. stock deliver long term returnsPortfolio Growth Summary & Consistent Return Investment Signals - newser.com
How to monitor Beam Therapeutics Inc. with trend dashboards2025 Buyback Activity & Weekly Stock Breakout Alerts - newser.com
Institutional scanner results for Beam Therapeutics Inc.Market Growth Review & Community Consensus Trade Signals - newser.com
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference - The Globe and Mail
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Oct 01 '25 |
Sale |
24.53 |
467 |
11,456 |
44,045 |
| Bellon Christine | Chief Legal Officer |
Oct 01 '25 |
Sale |
24.53 |
373 |
9,150 |
116,921 |
| Evans John M. | CEO |
Oct 01 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Sale |
24.63 |
25,000 |
615,668 |
986,667 |
| Evans John M. | CEO |
Oct 01 '25 |
Sale |
24.51 |
25,000 |
612,655 |
986,667 |
0.83%
1.59%
자본화:
|
볼륨(24시간):